Skip to main content

Redmile Group — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

104
Companies
$12.5B
Total invested
$136.1M
Avg. check
18
Industries
Biotechnology 21Health Care 14Therapeutics 14Medical 13Pharmaceutical 8Life Science 7+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 104
Kymera Therapeutics
December 2025

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

Biotechnology · Cambridge$602.0M Post-IPO Equity
Home Biosciences
November 2021

Home Biosciences is a European venture builder dedicated to biotech.

Biotechnology · Paris$15.0M Seed
Escient Pharmaceuticals
November 2022

Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.

Biotechnology · San Diego$120.0M Series C
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post-IPO Equity
Invivyd
November 2025

Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.

Biotechnology · Waltham$125.0M Post-IPO Equity
Augmedix
November 2023

Medical documentation, Point-of-care notifications, Structured data, Open ecosystem

Electronic Health Record (EHR) · San Francisco$25.0M Post-IPO Equity
Saluda Medical
November 2025

Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions.

Health Care · Bloomington$30.0M Venture - Series Unknown
Science 37
October 2021

Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.

Biotechnology · Culver City$200.0M Post-IPO Equity
Sphere Bio
October 2021

Sphere Bio specializes in tools for single cell analysis and isolation, facilitating discovery in the biotech field.

Biotechnology · Cambridge$41.4M Venture - Series Unknown
Repare Therapeutics
October 2021

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

Biotechnology · Saint Laurent$101.2M Post-IPO Equity
Nurix Therapeutics
October 2025

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Biotechnology · San Francisco$250.0M Post-IPO Equity
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post-IPO Equity
ADC Therapeutics
October 2025

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$60.0M Post-IPO Equity
Kalaris Therapeutics (formerly AlloVir)
December 2025

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Biotechnology · Houston$50.0M Post Ipo Equity
Wave Life Sciences
December 2025

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases

Biotechnology · Boston$350.0M Post Ipo Equity
Bambusa Therapeutics
November 2025

Bambusa Therapeutics operates as biotechnology company.

Biotechnology · BostonSeries A
Oruka Therapeutics
September 2025

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$180.0M Post Ipo Equity
Strand Therapeutics
August 2025

Strand Therapeutics is a biopharmaceutical company applying synthetic biology to RNA therapeutics to develop single dose mRNA treatments.

Biotechnology · Cambridge$153.0M Series B
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post Ipo Equity
Absci
July 2025

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI) · Vancouver$50.0M Post Ipo Equity
Quantum SI
July 2025

Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.

Biotechnology · Guilford$50.0M Post Ipo Equity
Atara Biotherapeutics
May 2025

Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.

Biotechnology · South San Francisco$16.0M Post Ipo Equity
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
CorVent Medical
June 2024

We provide simple, sophisticated respiratory solutions for post-ICU and home environments, eliminating unnecessary cost and complexity.

Health Care · Fargo$3.0M Grant

Where Redmile Group invests

Biotechnology21
Health Care14
Therapeutics14
Medical13
Pharmaceutical8
Life Science7

About Redmile Group's portfolio

How many companies has Redmile Group invested in?

Redmile Group has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Redmile Group invest in?

Redmile Group's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 18 different industry categories.

What is Redmile Group's largest investment?

Among tracked funding rounds, Kymera Therapeutics received $602.0M in a Post-IPO Equity round. Redmile Group's total known invested capital is $12.5B.

What is the average investment size for Redmile Group?

Redmile Group's average investment size is $136.1M across its portfolio of 104 companies.

What are Redmile Group's most recent investments?

Recent Redmile Group portfolio additions include Kymera Therapeutics, Home Biosciences, Escient Pharmaceuticals, Replimune Group, Invivyd. These companies were founded in 2020 or later.

Reach the founders behind these 104 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →